DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mirtazapine (Mirtazapine) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Associated with Discontinuation of Treatment


Approximately 16 % of the 453 patients who received mirtazapine tablets in US 6-week controlled clinical trials discontinued treatment due to an adverse experience, compared to 7 % of the 361 placebo-treated patients in those studies. The most common events (≥ 1%) associated with discontinuation and considered to be drug related (i.e., those events associated with dropout at a rate at least twice that of placebo) included in Table 2.


Table 2: Common Adverse Events Associated With Discontinuation of Treatment in 6-Week U.S.
Mirtazapine Trials


Adverse Event
Percentage of Patients Discontinuing with Adverse Event
Mirtazapine
(n=453)
Placebo
(n=361)
  Somnolence
10.4%
2.2%
  Nausea
1.5%
0%

Commonly Observed Adverse Events in U.S. Controlled Clinical Trials


The most commonly observed adverse events associated with the use of mirtazapine tablets (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (mirtazapine incidence at least twice that for placebo) are listed in Table 3.


Table 3: Common Treatment –Emergent Adverse Events Associated With the Use of Mirtazapine
in 6-Week U.S. Trials


Adverse Event
Percentage of Patients Reporting Adverse Event
Mirtazapine
(n=453)
Placebo
(n=361)
  Somnolence
54%
18%
  Increased Appetite
17%
2%
  Weight Gain
12%
2%
  Dizziness
7%
3%

Adverse Events Occurring at an Incidence of 1% or More Among Mirtazapine-Treated Patients

Table 4 enumerates adverse events that occurred at an incidence of 1% or more, and were more frequent than in the placebo group, among mirtazapine tablets-treated patients who participated in short-term US placebo-controlled trials in which patients were dosed in a range of 5 to 60 mg/day. This table shows the percentage of patients in each group who had at least 1 episode of an event at some time during their treatment. Reported adverse events were classified using a standard COSTART-based dictionary terminology.



The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side-effect incidence rate in the population studied.




Table 4: Incidence of Adverse Clinical Experiences1 (≥1%) in Short-Term U.S. Controlled Studies


Body System Adverse Clinical Experience Mirtazapine
(n=453)
Placebo
(n=361)
1Events reported by at least 1% of patients treated with mirtazapine are included, except the following events, which had an incidence on placebo grater than or equal to mirtazapine: headache, infection, pain, chest pain, palpitation, tachycardia, postural hypotension, nausea, dyspepsia, diarrhea, flatulence, insomnia, nervousness, libido decreased, hypertonia, pharyngitis, rhinitis, sweating, amblyopia, tinnitus, taste perversion.
  Body as a Whole
    Asthenia
8%
5%
    Flu Syndrome
5%
3%
    Back Pain
2%
1%
  Digestive System
 
 
    Dry Mouth
25%
15%
    Increased Appetite
17%
2%
    Constipation
13%
7%
  Metabolic and Nutritional Disorders
    Weight Gain
12%
2%
    Peripheral Edema
2%
1%
    Edema
1%
0%
  Musculoskeletal System
    Myalgia
2%
1%
  Nervous System
    Somnolence
54%
18%
    Dizziness
7%
3%
    Abnormal Dreams
4%
1%
    Thinking Abnormal
3%
1%
    Tremor
2%
1%
    Confusion
2%
0%
  Respiratory System
    Dyspnea
1%
0%
  Urogenital System
    Urinary Frequency
2%
1%

ECG Changes


The electrocardiograms for 338 patients who received mirtazapine tablets and 261 patients who received placebo in 6-week, placebo-controlled trials were analyzed. Prolongation in QTc ≥ 500 msec was not observed among mirtazapine-treated patients; mean change in QTc was +1.6 msec for mirtazapine and –3.1 msec for placebo. Mirtazapine was associated with a mean increase in heart rate of 3.4 bpm, compared to 0.8 bpm for placebo. The clinical significance of these changes is unknown.

Other Adverse Events Observed During the Premarketing Evaluation of Mirtazapine


During its premarketing assessment, multiple doses of mirtazapine tablets were administered to 2796 patients in clinical studies. The conditions and duration of exposure to mirtazapine varied greatly, and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.

In the tabulations that follow, reported adverse events were classified using a standard COSTART-based dictionary terminology. The frequencies presented, therefore, represent the proportion of the 2796 patients exposed to multiple doses of mirtazapine who experienced an event of the type cited on at least 1 occasion while receiving mirtazapine. All reported events are included except those already listed in Table 4, those adverse experiences subsumed under COSTART terms that are either overly general or excessively specific so as to be uninformative, and those events for which a drug cause was very remote.

It is important to emphasize that, although the events reported occurred during treatment with mirtazapine, they were not necessarily caused by it.

Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on 1 or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. Only those events not already listed in Table 4 appear in this listing. Events of major clinical importance are also described in the WARNINGS and PRECAUTIONS sections.

Body as a Whole: frequent: malaise, abdominal pain, abdominal syndrome acute; infrequent: chills, fever, face edema, ulcer, photosensitivity reaction, neck rigidity, neck pain, abdomen enlarged; rare: cellulitis, chest pain substernal.

Cardiovascular System: frequent: hypertension, vasodilatation; infrequent: angina pectoris, myocardial infarction, bradycardia, ventricular extrasystoles, syncope, migraine, hypotension; rare: atrial arrhythmia, bigeminy, vascular headache, pulmonary embolus, cerebral ischemia, cardiomegaly, phlebitis, left heart failure.

Digestive System: frequent: vomiting, anorexia; infrequent: eructation, glossitis, cholecystitis, nausea and vomiting, gum hemorrhage, stomatitis, colitis, liver function tests abnormal; rare:  tongue discoloration, ulcerative stomatitis, salivary gland enlargement, increased salivation, intestinal obstruction, pancreatitis, aphthous stomatitis, cirrhosis of liver, gastritis, gastroenteritis, oral moniliasis, tongue edema.

Endocrine System: rare: goiter, hypothyroidism.

Hemic and Lymphatic System: rare: lymphadenopathy, leukopenia, petechia, anemia, thrombocytopenia, lymphocytosis, pancytopenia.

Metabolic and Nutritional Disorders: frequent: thirst; infrequent: dehydration, weight loss; rare: gout, SGOT increased, healing abnormal, acid phosphatase increased, SGPT increased, diabetes mellitus, hyponatremia.

Musculoskeletal System:   frequent: myasthenia, arthralgia; infrequent:  arthritis, tenosynovitis; rare: pathologic fracture, osteoporosis fracture, bone pain, myositis, tendon rupture, arthrosis, bursitis.

Nervous System: frequent: hypesthesia, apathy, depression, hypokinesia, vertigo, twitching, agitation, anxiety, amnesia, hyperkinesia, paresthesia; infrequent: ataxia, delirium, delusions, depersonalization, dyskinesia, extrapyramidal syndrome, libido increased, coordination abnormal, dysarthria, hallucinations, manic reaction, neurosis, dystonia, hostility, reflexes increased, emotional lability, euphoria, paranoid reaction; rare:  aphasia, nystagmus, akathisia (psychomotor restlessness), stupor, dementia, diplopia, drug dependence, paralysis, grand mal convulsion, hypotonia, myoclonus, psychotic depression, withdrawal syndrome, serotonin syndrome.

Respiratory System:  frequent:  cough increased, sinusitis; infrequent:  epistaxis, bronchitis, asthma, pneumonia; rare: asphyxia, laryngitis, pneumothorax, hiccup.

Skin and Appendages: frequent:  pruritus, rash; infrequent:  acne, exfoliative dermatitis, dry skin, herpes simplex, alopecia; rare: urticaria, herpes zoster, skin hypertrophy, seborrhea, skin ulcer.

Special Senses: infrequent: eye pain, abnormality of accommodation, conjunctivitis, deafness, keratoconjunctivitis, lacrimation disorder, glaucoma, hyperacusis, ear pain; rare: blepharitis, partial transitory deafness, otitis media, taste loss, parosmia.

Urogenital System: frequent: urinary tract infection; infrequent: kidney calculus, cystitis, dysuria, urinary incontinence, urinary retention, vaginitis, hematuria, breast pain, amenorrhea, dysmenorrhea, leukorrhea, impotence; rare: polyuria, urethritis, metrorrhagia, menorrhagia, abnormal ejaculation, breast engorgement, breast enlargement, urinary urgency.

Other Adverse Events Observed During Postmarketing Evaluation of Mirtazapine


Adverse events reported since market introduction, which were temporally (but not necessarily casually) related to mirtazapine therapy, include 4 cases of the ventricular arrhythmia torsades de pointes. In 3 of the 4 cases, however, concomitant drugs were implicated. All patients recovered.

Cases of severe skin reactions, including Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have also been reported.



REPORTS OF SUSPECTED MIRTAZAPINE SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Mirtazapine. The information is not vetted and should not be considered as verified clinical evidence.

Possible Mirtazapine side effects / adverse reactions in 74 year old female

Reported by a physician from France on 2011-10-03

Patient: 74 year old female

Reactions: Hyperosmolar State, Hyponatraemia, Asthenia

Suspect drug(s):
Mirtazapine



Possible Mirtazapine side effects / adverse reactions in 63 year old female

Reported by a pharmacist from Germany on 2011-10-03

Patient: 63 year old female weighing 85.0 kg (187.0 pounds)

Reactions: Herpes Ophthalmic

Suspect drug(s):
Valproic Acid
    Administration route: Oral

Seroquel
    Administration route: Oral

Venlafaxine HCL
    Administration route: Oral

Mirtazapine
    Administration route: Oral



Possible Mirtazapine side effects / adverse reactions in 56 year old female

Reported by a health professional (non-physician/pharmacist) from Turkey on 2011-10-03

Patient: 56 year old female

Reactions: Refusal of Treatment by Patient, Drug Ineffective, Suicide Attempt

Adverse event resulted in: hospitalization

Suspect drug(s):
Risperidone

Sertraline Hydrochloride
    Indication: Depression

Mirtazapine
    Indication: Depression

Risperidone

Risperidone
    Indication: Depression



See index of all Mirtazapine side effect reports >>

Drug label data at the top of this Page last updated: 2014-06-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017